Rising Prevalence Of Chronic Diseases Fuels Growth In The Cancer Biologics Market Is Supporting Development Across The Cancer biologics Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Size Of The Cancer biologics Market In 2026 And How Much Will It Reach By 2030?

The cancer biologics market size has seen robust growth in recent years. It is projected to expand from $129.05 billion in 2025 to $140.88 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.2%. This historical expansion is attributable to factors such as the increasing global prevalence of cancer, a growing demand for advanced cancer therapies, heightened oncology research activities, the limited effectiveness of conventional chemotherapy, and the proliferation of hospital-based cancer treatment centers.

The cancer biologics market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach **$203.29 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 9.6%.** This projected growth is driven by several factors, including breakthroughs in cell and gene therapy platforms, an increase in approvals for new biologics, the expansion of personalized oncology treatments, greater investment in research and development for cancer biologics, and increased biologics manufacturing capabilities. Key developments expected during this period involve the increasing embrace of immunotherapy and targeted biologic treatments, a greater application of monoclonal antibodies in oncology, the proliferation of cell and gene therapy-based cancer interventions, the broadening of cancer vaccine development initiatives, and an intensified focus on combination biologic therapies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp

What Important Drivers Are Powering The Cancer biologics Market Growth?

The increasing prevalence of chronic diseases stands as a significant factor driving the growth of the cancer biologics market. Chronic disorders are conditions that endure over prolonged periods, impairing the health of affected individuals, with cancer being a prevalent example of such a chronic disease. The most commonly observed cancers include breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. For example, in February 2024, data published by the Centers for Disease Control and Prevention (CDC), a US-based public health agency, indicated that an expanding proportion of people in America are contending with multiple chronic conditions, with 42% having two or more, and 12% dealing with five or more. Consequently, the rising occurrence of chronic diseases is expected to propel the cancer biologics market’s expansion in the years ahead.

What Key Segment Areas Are Included In The Cancer biologics Market Assessment?

The cancer biologics market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types

2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications

3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Vaccines: Therapeutic Cancer Vaccines, Preventive Cancer Vaccines

3) By Cell And Gene Therapy: CAR T-Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Oncolytic Virus Therapy

4) By Other Types: Cytokines, Growth Factors, Fusion Proteins

Which Trends Are Influencing The Direction Of The Cancer biologics Market?

Major companies in the cancer biologics market are prioritizing the development of innovative therapies like bispecific antibodies and biomarker guided biologics to boost treatment efficacy and more effectively pinpoint specific cancer cells. Bispecific antibodies are a next-generation biologic approach that can simultaneously bind to two distinct epitopes or targets, while biomarker guided biologics are tailored to specifically target tumor cells identified through certain molecular markers. For instance, in November 2024, Jazz Pharmaceuticals Public Limited Company, a global biopharmaceutical company based in Dublin, secured approval from the U.S. Food & Drug Administration (FDA) for the accelerated approval of Ziihera (zanidatamab hrii) for adults suffering from previously treated, unresectable or metastatic HER2 positive (IHC 3+) biliary tract cancer (BTC). This approval signifies the introduction of the first and only dual HER2 targeted bispecific antibody for this specific indication, thereby extending the reach of HER2 targeted biologic therapy into a new type of tumor beyond its conventional applications.

Which Firms Are Competing In The Cancer biologics Market?

Major companies operating in the cancer biologics market are AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer Inc., Celgene Corporation, Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc.

Access The Complete Cancer biologics Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

What Is The Largest Regional Market In The Cancer biologics Market?

North America was the largest region in the cancer biologics market in 2025. The Middle East is expected to be the fastest-growing region in the global cancer biologics market share during the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Cancer biologics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp

Browse Through More Reports Similar to the Global Cancer biologics Market 2026, By The Business Research Company

Point Of Care Diagnostics Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-devices-and-equipment-global-market-report

Cell Culture Consumables And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-culture-consumables-and-equipment-global-market-report

Metabolomics Market Report 2026

https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795